Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
Completed · Phase 3
Conditions studied: Kidney Neoplasms
In brief
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer.
Key facts
- Study ID
- NCT00920816
- Run by
- Pfizer
- People needed
- 492
- Starts
- 2009-08-25
- Expected to finish
- 2021-04-29
- Last updated by the study team
- 2022-05-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically documented metastatic renal cell cancer with a component of clear cell histology.
- Evidence of measurable disease.
- Patients with mRCC must have received no prior systemic first-line therapy or must have progressive disease per RECIST (version 1.0) after one prior systemic first line regimen for metastatic disease containing sunitinib, cytokine(s), or both.
You may not qualify if…
- Prior treatment for metastatic renal cell cancer with more that one systemic first line therapy.
- Major surgery less that 4 weeks or radiation less than 2 weeks of starting study drug.
Where it is running
- Advanced Medical Specialties — Miami, Florida, United States
- Illinois Cancer Specialists — Arlington Heights, Illinois, United States
- Illinois Cancer Specialists — Niles, Illinois, United States
- Indiana University Health Central Indiana Cancer Centers — Carmel, Indiana, United States
- Indiana University Health Central Indiana Cancer Centers — Fishers, Indiana, United States
- Indiana University Health Central Indiana Cancer Centers — Greenfield, Indiana, United States
- Indiana University Health Central Indiana Cancer Centers — Indianapolis, Indiana, United States
- Indiana University Health Central Indiana Cancer Centers — Indianapolis, Indiana, United States
- Missouri Cancer Associates — Columbia, Missouri, United States
- Nebraska Methodist Hospital — Omaha, Nebraska, United States
- Comprehensive Cancer Centers of Nevada — Henderson, Nevada, United States
- US Oncology West Region — Henderson, Nevada, United States
- Comprehensive Cancer Centers of Nevada — Henderson, Nevada, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
- Hematology-Oncology Associates of Northern NJ, PA — Morristown, New Jersey, United States
- Hematology-Oncology Associates of Northern NJ, PA — Parsippany, New Jersey, United States
- New York Oncology Hematology, PC — Albany, New York, United States
- New York Oncology Hematology, PC — Albany, New York, United States
- New York Oncology Hematology, PC — Latham, New York, United States
- New York Oncology Hematology, PC — Rexford, New York, United States
- New York Oncology Hematology, PC — Troy, New York, United States
- Raleigh Hematology Oncology Associates — Cary, North Carolina, United States
- Advanced Medical Specialties — Miami, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.